Volastra Therapeutics Announces Appointment of David P. Southwell as Chief Executive Officer
"We are delighted to welcome David to Volastra," said Sandi Peterson, Chair of Volastra's Board of Directors. "David's deep biotech leadership experience and proven track record make him the ideal CEO to lead Volastra through this exciting period of growth."
"Volastra has pioneered novel therapeutic approaches in the emerging field of chromosomal instability, which is central to the progression of many cancers," said David Southwell. "With exciting early clinical data and a world-class team of management and investors, Volastra is well-positioned to be a leader in oncologic therapies."
Mr. Southwell has built a strong foundation of financial, operational and strategic expertise throughout his career leading innovative biotechnology and pharmaceutical companies. He most recently served as President and Chief Executive Officer of TScan Therapeutics, an immune-oncology company advancing T-cell receptor-based therapies. Prior to that, he was President, Chief Executive Officer, and Board member of Inotek Pharmaceuticals, guiding the company through its merger with Rocket Pharmaceuticals in early 2018. Mr. Southwell also held senior executive roles as CFO at Human Genome Sciences through its acquisition by GlaxoSmithKline, and at Sepracor Inc., where he served as Executive Vice President and CFO for over a decade. He has served on the Boards of several public and private life sciences companies and currently serves on the Boards of PTC Therapeutics and Rocket Pharmaceuticals.
Mr. Southwell succeeds Charles Hugh-Jones, who has led Volastra Therapeutics from its inception as CEO. The Board greatly appreciates Charles' leadership, vision and substantial contributions to the Company's success over the past 5 years. He will continue as an advisor to the Company.
Separately, Volastra will be presenting dose escalation data from its first-in-human VLS-1488 trial in an oral presentation on June 2nd at the 2025 ASCO Annual Meeting.
About Volastra TherapeuticsVolastra Therapeutics is a clinical-stage biotechnology company pioneering novel approaches to the treatment of cancer by targeting chromosomal instability. The company leads the field with two differentiated, oral KIF18A inhibitors, VLS-1488 and sovilnesib (formerly AMG-650). Both assets are currently being evaluated in Phase 1 clinical trials for platinum resistant ovarian cancer and other advanced solid tumors. Volastra is also developing new techniques to understand the biology of chromosomal instability and leveraging these insights to drive forward a preclinical pipeline of therapies against innovative targets. Volastra was founded in 2019 by Lewis Cantley, Ph.D., Samuel Bakhoum, M.D., Ph.D., and Olivier Elemento, Ph.D., and is funded by key investors including Polaris Partners, ARCH Ventures, B-Capital, Droia Ventures, Vida Ventures, Catalio Capital Management and Eli Lilly & Company. Notable partners include Tailor Bio and Microsoft.
For more information, please visit www.volastratx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527677059/en/
Contacts
Media Contact: Maeve Morse-SeavernsVolastra Therapeuticsmedia@volastratx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
7 hours ago
- New York Times
Dr. David Altchek, esteemed Mets medical director, dies at 68
Dr. David Altchek, one of baseball's pre-eminent elbow surgeons and the New York Mets' medical director for the past 20 years, passed away Thursday at the age of 68. Altchek had revealed to colleagues last year that he had been diagnosed with a brain tumor. A graduate of Columbia and Cornell Medical College, Altchek began his association with New York City's Hospital for Special Surgery in 1987. He joined the Mets organization in 1991 as the head team physician, serving in that role for 11 years. He returned to the Mets in 2005 as the club's medical director. If a Mets player required Tommy John surgery over the past 35 years, there's a good chance Altchek performed it — from Todd Hundley through Jacob deGrom, Steven Matz, Zack Wheeler and Noah Syndergaard. Altchek estimated that he performed around 2,400 Tommy John surgeries. RIP Dr. Altchek @HSpecialSurgery — Justin Topa (@Justin_Topa) July 17, 2025 'We are deeply saddened by the passing of Dr. David Altchek,' Mets owners Steve and Alex Cohen said in a statement. 'Renowned worldwide for his surgical expertise, he was equally admired for the compassion and care he showed to our players. We extend our heartfelt condolences to his family, friends and colleagues.' 'Known for his technical brilliance and pioneering work in orthopedic surgery, Dr. Altchek had a profoundly positive impact on our organization,' the Hospital for Special Surgery said in a statement. 'His legacy endures among the thousands of grateful patients whose lives he touched with skill and compassion, and among the many surgeons around the world who carry forward his knowledge and example. His contributions will continue to inspire us all and elevate the field. He will be dearly missed.'
Yahoo
7 hours ago
- Yahoo
OKC bond proposal pays for street improvements
OKLAHOMA CITY (KFOR) — There's $2.7 billion proposed in the upcoming bond election for Oklahoma City. Over half of that is going to street repairs, sidewalk upgrades, and more. The city has used bonds to make improvements since before statehood. 'This is the way we pay for our infrastructure in our city are these bond issues,' said Mayor David Holt, (R), Oklahoma City. The proposal funds a variety of projects from sidewalks to bridges to parks to the transit system. 'We approved one most recently in 2017 and it's time to do it again,' said Mayor Holt. LOCAL NEWS: 'Emotionally overwhelming': Architect of new OKC arena shares inspiration, addresses feedback Mayor David Holt said this is a routine vote that happens every few years and the money is something that has funded city streets and other improvements for the last half century. Voters have 11 propositions to vote on. So if one doesn't pass, like street improvements, Mayor Holt said the infrastructure will stay the same. 'If we didn't pass it, there's no more fixing of anything in Oklahoma City until we get something like this approved,' said Mayor Holt. The city said there are 547 projects within the bond proposal. 382 of those are for streets and sidewalks. 25 are for bridges. 'OKC has used bonds to pay for its core infrastructure since before statehood. When voters go to the polls on Oct. 14, they will vote on 11 separate propositions covering everything from streets and bridges to parks and drainage. If residents vote no on a proposition, the improvements listed in the bond won't be made. OKC voters rejected park bond improvements from 1974 to 1995. The disinvestment led to outdated pools, playground equipment and fewer people using the parks system for two decades.' City of Oklahoma City The city also wants to remind voters that the bond won't raise property tax. 'I'm optimistic that we will, but we're certainly here to talk about it, answer any questions, but it's been well crafted and discussed for the last year,' said Mayor Holt. The bond election is October 14th. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Forbes
12 hours ago
- Forbes
DoD Is The Largest Investor In Only American Rare Earth Mineral Mine
Rare earth and critical minerals are essential to powering today's modern and digital world Under the 1933 Buy American Act and the 1941 Berry Amendment, the United States military is generally required to buy American-made products. The laws further prioritize domestic sourcing for goods, and that products for military use contain a certain percentage of U.S. components and materials. Where that has been a problem is in the increasingly reliance on components that require rare earth minerals, which the United States has a limited supply of, while upwards of 70% are imported from China. To help address the issue, the U.S. Department of Defense announced last week that it had acquired a 15% stake in the MP Materials mine, becoming the company's largest shareholder. MP Materials, the operator of the only American rare earths mine, received a $400 million investment from the Pentagon, which will help fund the processing capabilities at its Mount Pass, California, facility and enable the construction of a second magnet manufacturing plant. "It's strategically important for the Pentagon to ensure that its Tier 1 industrial base has access to U.S.-sourced rare earth metals and magnets," explained David Argyle, CEO of REalloys Inc., a company focused on the production of rare earth elements and high-performance magnet materials. "The MP DoD transaction provides a very healthy base load of supply to meet demand," Argyle added, but acknowledged that additional US sources need to be available commencing in 2026, 2027, and beyond. Greater Investment Is Needed There has already been speculation that President Donald Trump could use emergency powers to allow the United States to gain greater control over domestic industries and resources. The Defense Production Act, a Cold War-era law that grants the president significant emergency authority to control domestic industries, was invoked by Trump during his first term and by former President Joe Biden during the pandemic. However, investments are also needed, suggested Brandon Daniels, CEO of AI supply chain company Exiger. "Critical minerals are the lifeblood of our defense capabilities. Everything from specialized engine components for high heat environments to navigation systems demands rare earth minerals at the beginning of the supply chain," said Daniels. "It's a national security imperative that the defense department use its resources to create sustainable independent streams of these resources." The $400 million investment shouldn't be seen as too little or too late. "The Pentagon is doing this because it's not always economically viable to invest the capital expenditure at the beginning of the process, and the U.S. ought to accelerate its access to these minerals," added Daniels. Such strategic investment in rare earths and critical minerals is a crucial step in securing our domestic supply chain and enhancing national security. Still, it is just part of the solution. "The defense industry depends on these strategic materials for everything from weaponry, base operations, to communications and other additional technologies," noted David Klanecky, CEO of lithium battery recycling firm Cirba Solutions. "Investment by the Department of Defense demonstrates a prioritization of this key market, brings urgency to the sector, and underscores the importance of developing a reliable supply at home rather than depending on raw material imports from foreign entities of concern." Waste Not, Want Not Without stable access to rare earths and critical minerals, our national security is at significant risk. To this end, the U.S. military needs to be far less disposable. As with consumer products that end up in landfills, a vast amount of valuable materials is never harvested and reused. "It is also important to look at the supply chain holistically and invest in all domestic manufacturing," Klanecky added. "For example, battery recycling can significantly boost domestic production and refinement of critical minerals, and it is one of the most immediate and scalable ways to secure supply and keep valuable materials in circulation in the U.S. long after they've been extracted." More Efforts Need To Be Made The $400 million investment by the Pentagon should be viewed as a positive first step, but it is far from resolving a problem that has been decades in the making. "The one mining project won't be enough to fulfill all demand for all rare earths that are used in advanced technologies," warned Daniels. "But it is a big step in the right direction," Daniels continued. "Between this type of mining and the advancements in recycling, we can achieve independence for many of our most critical rare earths. For instance, with coal ash leaching in the United States, we could generate enough germanium to supply all of our Semiconductor, Photovoltaic, and Fiber Optic cable needs." The growing need for rare earths is just one of several problems that the Pentagon faces, along with manufacturing supply chain challenges, an aging workforce at America's shipyards, and cost overruns on nearly all its programs. However, the demand for rare earths needs to be taken as seriously as the other issues, yet there is no easy solution. "Rare earth and critical minerals are essential to powering today's modern and digital world. Meeting the growing demand for these materials will require a comprehensive strategy that includes investment, partnerships, and an overall diversified approach across extraction, refinement, and recycling," said Klanecky. "Taking this holistic view of the supply chain is necessary if the U.S. wants a long-term solution to creating a stable domestic supply and enabling the country to achieve national security goals."
